StockNews.com Initiates Coverage on Aeterna Zentaris (NASDAQ:AEZS)

Research analysts at StockNews.com started coverage on shares of Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) in a research note issued to investors on Wednesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Aeterna Zentaris Stock Down 6.2 %

Shares of Aeterna Zentaris stock opened at $4.41 on Wednesday. The company has a market capitalization of $7.89 million, a price-to-earnings ratio of -0.30 and a beta of 1.56. Aeterna Zentaris has a 52 week low of $3.96 and a 52 week high of $12.80. The stock’s 50-day simple moving average is $7.34 and its 200-day simple moving average is $7.63.

Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last released its earnings results on Tuesday, May 14th. The biopharmaceutical company reported ($4.74) earnings per share for the quarter. Aeterna Zentaris had a negative net margin of 760.32% and a negative return on equity of 83.45%.

About Aeterna Zentaris

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis.